Evidence-based guidelines for prevention and therapy of venous thromboembolism
UNLABELLED: Recently, evidence-based guidelines for the prevention and therapy of venous thromboembolism have been published. Prophylaxis: in General Surgery patients with moderate to severe risk need to be treated with unfractioned (UFH) or low molecular weight (LMWH) heparin. Non pharmacological methods must be reserved to patients with high hemorrhagic risk and in association to heparin to patients with particularly high thromboembolic risk. In high risk Ortopedic Surgery prophylaxis with high doses LMWH or oral anticoagulants (OA) is indicated. Il Neurosurgical Surgery and in politraumatized patients prophylaxis must be individualized taking account of hemorrhagic risk; patients with acute medullary lesion with paraplegia must be treated with LMWH. In Internal Medicine conditions which determine prolonged bed rest need prophylaxis with UFH or LMWH. In pregnancy, pharmacological prophylaxis is indicated only in cases of preceding thrombotic events or documented congenital risk factors.
THERAPY: deep venous thrombosis or sub-massive pulmonary embolism must be treated with anticoagulant doses of UFH or LMWH (100 U antiXa/Kg twice daily). OA must be continued for a time identifiable on the basis of underlying disease. In massive or sub-massive pulmonary embolism with hemodynamic instability thrombolysis is indicated. In heparin induced thrombocytopenia alternative antithrombotic treatments must be employed.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2000 |
|---|---|
| Erschienen: |
2000 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Minerva cardioangiologica - 48(2000), 12 Suppl 1 vom: 15. Dez., Seite 27-35 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Linee guida basate sull'evidenza per la prevenzione e terapia del tromboembolismo venoso |
|---|
| Beteiligte Personen: |
Falciani, M [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 19.04.2001 Date Revised 28.07.2014 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM111639875 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM111639875 | ||
| 003 | DE-627 | ||
| 005 | 20231222160036.0 | ||
| 007 | tu | ||
| 008 | 231222s2000 xx ||||| 00| ||ita c | ||
| 028 | 5 | 2 | |a pubmed24n0373.xml |
| 035 | |a (DE-627)NLM111639875 | ||
| 035 | |a (NLM)11253337 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Falciani, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evidence-based guidelines for prevention and therapy of venous thromboembolism |
| 246 | 3 | 3 | |a Linee guida basate sull'evidenza per la prevenzione e terapia del tromboembolismo venoso |
| 264 | 1 | |c 2000 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2001 | ||
| 500 | |a Date Revised 28.07.2014 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a UNLABELLED: Recently, evidence-based guidelines for the prevention and therapy of venous thromboembolism have been published. Prophylaxis: in General Surgery patients with moderate to severe risk need to be treated with unfractioned (UFH) or low molecular weight (LMWH) heparin. Non pharmacological methods must be reserved to patients with high hemorrhagic risk and in association to heparin to patients with particularly high thromboembolic risk. In high risk Ortopedic Surgery prophylaxis with high doses LMWH or oral anticoagulants (OA) is indicated. Il Neurosurgical Surgery and in politraumatized patients prophylaxis must be individualized taking account of hemorrhagic risk; patients with acute medullary lesion with paraplegia must be treated with LMWH. In Internal Medicine conditions which determine prolonged bed rest need prophylaxis with UFH or LMWH. In pregnancy, pharmacological prophylaxis is indicated only in cases of preceding thrombotic events or documented congenital risk factors | ||
| 520 | |a THERAPY: deep venous thrombosis or sub-massive pulmonary embolism must be treated with anticoagulant doses of UFH or LMWH (100 U antiXa/Kg twice daily). OA must be continued for a time identifiable on the basis of underlying disease. In massive or sub-massive pulmonary embolism with hemodynamic instability thrombolysis is indicated. In heparin induced thrombocytopenia alternative antithrombotic treatments must be employed | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 650 | 7 | |a calcium heparin |2 NLM | |
| 650 | 7 | |a 37270-89-6 |2 NLM | |
| 650 | 7 | |a Heparin |2 NLM | |
| 650 | 7 | |a 9005-49-6 |2 NLM | |
| 650 | 7 | |a Streptokinase |2 NLM | |
| 650 | 7 | |a EC 3.4.- |2 NLM | |
| 650 | 7 | |a Urokinase-Type Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.73 |2 NLM | |
| 700 | 1 | |a Dilaghi, B |e verfasserin |4 aut | |
| 700 | 1 | |a Conti, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Caciolli, S |e verfasserin |4 aut | |
| 700 | 1 | |a Gensini, G F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Minerva cardioangiologica |d 1953 |g 48(2000), 12 Suppl 1 vom: 15. Dez., Seite 27-35 |w (DE-627)NLM000140988 |x 1827-1618 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2000 |g number:12 Suppl 1 |g day:15 |g month:12 |g pages:27-35 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2000 |e 12 Suppl 1 |b 15 |c 12 |h 27-35 | ||